Stock Analiz

Radiopharm Theranostics Ltd RADX

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.76Market cap $11M
Open the interactive analysis →

Radiopharm Theranostics Ltd (RADX) is a healthcare company listed in the US with a market value of about $11M. In fiscal year 2026 it had revenue of $2M and net income of -$38M, a net margin of -2057.5%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -89%.

About Radiopharm Theranostics

Radiopharm Theranostics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $292359 in 2023 to $2M in 2026, growth of about 85.6% a year. It was profitable in 0 of the last 4 years in our data. Its share count fell by 29% over three years (buybacks).

Score: 1.2 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health4/5
Shareholder returns1/5

Checks passed

  • Profit margin improving
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.3
P/B0.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-324.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)1114.3%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-9639.4%
ROIC (5-yr avg.)-88.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 4 years

Fiscal year2026202520242023
Revenue$2M$4M$299228$292359
Net income-$38M-$38M-$48M-$35M
Free cash flow-$36M——-$23M
EPS (diluted)$-3.76$-2.65$-3.32$-2.39
Net margin-2057.5%-1055.3%-16024.3%-11838.6%
ROIC—-70.3%-136.3%-59.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Radiopharm Theranostics pay a dividend?

Not currently.

Is Radiopharm Theranostics a good stock to buy?

We do not give buy or sell advice. Radiopharm Theranostics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.